Health Care·Biotechnology·$3.7B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.85 | N/A | -18.06% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.85 | N/A | -18.06% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Management expressed concerns about the impact of external factors on their operations. They remain focused on strategic initiatives to drive future growth.
Management highlighted ongoing challenges in the current market environment.
They emphasized their commitment to long-term growth despite short-term setbacks.
Twist Bioscience's earnings report indicates ongoing challenges, particularly reflected in their EPS miss. The stock reacted negatively, dropping 1.48%, likely due to investor concerns about the company's short-term performance. Without revenue figures or guidance, uncertainty remains about their future direction.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
SEMPRA
May 4, 2020